KTTA Key Statistics, Chart & Performance
The current stock price of KTTA is 0.8452 USD. In the past month the price decreased by -28.97%. In the past year, price decreased by -55.75%.
KTTA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to KTTA. When comparing the yearly performance of all stocks, KTTA is a bad performer in the overall market: 83.58% of all stocks are doing better.
KTTA Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
KTTA Forecast & Estimates
7 analysts have analysed KTTA and the average price target is 3.06 USD. This implies a price increase of 262.04% is expected in the next year compared to the current price of 0.8452.
KTTA Ownership
KTTA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.88 | 398.79B | ||
| AMGN | AMGEN INC | 15.76 | 185.60B | ||
| GILD | GILEAD SCIENCES INC | 17.45 | 177.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.19 | 119.76B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.01 | 79.35B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 664.92 | 44.80B | ||
| INSM | INSMED INC | N/A | 32.84B | ||
| NTRA | NATERA INC | N/A | 31.89B | ||
| BIIB | BIOGEN INC | 10.7 | 26.27B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18 | 20.45B | ||
| INCY | INCYTE CORP | 15.99 | 20.16B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.45B |
Related stock screener links
About KTTA
Company Profile
Pasithea Therapeutics Corp. is a biotechnology company focused on the research and discovery of new and treatments for psychiatric and neurological disorders. The company is headquartered in Miami Beach, Florida and currently employs 4 full-time employees. The company went IPO on 2021-08-13. The firm is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.
Company Info
PASITHEA THERAPEUTICS CORP
1111 Lincoln Road, Suite 500
Miami Beach FLORIDA US
CEO: Tiago Reis Marques
Employees: 4
Phone: 17025144174
PASITHEA THERAPEUTICS CORP / KTTA FAQ
What does KTTA do?
Pasithea Therapeutics Corp. is a biotechnology company focused on the research and discovery of new and treatments for psychiatric and neurological disorders. The company is headquartered in Miami Beach, Florida and currently employs 4 full-time employees. The company went IPO on 2021-08-13. The firm is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.
What is the stock price of PASITHEA THERAPEUTICS CORP today?
The current stock price of KTTA is 0.8452 USD. The price decreased by -1.84% in the last trading session.
Does KTTA stock pay dividends?
KTTA does not pay a dividend.
How is the ChartMill rating for PASITHEA THERAPEUTICS CORP?
KTTA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Would investing in PASITHEA THERAPEUTICS CORP be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on KTTA.
What is PASITHEA THERAPEUTICS CORP worth?
PASITHEA THERAPEUTICS CORP (KTTA) has a market capitalization of 18.84M USD. This makes KTTA a Nano Cap stock.